Phase 3 N=236 Hysterectomy and Levonorgestrel Releasing Intrauterine System (LNG-IUS) in the Treatment of Menorrhagia
Menorrhagia
Primary: HRQoL (Health Related Quality of Life) — 0.08; 0.10 points on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=52 Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy
Benign Uterine Disease
Primary: The Primary Endpoint of This Study is Time Difference Between Cauterizing One Side of the Uterine Attachments, From the Round Ligament to the Uterine Artery on One Side…
N/A N=700 Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer
Cervical Cancer
Primary: Pelvic Recurrence Rate at 3 Years — 2.17; 2.52 percentage of participants
N/A N=70 Hysterectomy by Transabdominal Laparoscopy or NOTES
Uterine Diseases
Primary: Successful Removal of the Uterus Without Conversion to Another Technique — 35; 35 Participants — p=0.0221
N/A N=50 Robot Assisted Laparoscopic Hysterectomy vs. Abdominal Hysterectomy in Endometrial Cancer
Endometrial Cancer
Primary: Health Related Quality of Life (HRQoL) — 0.34; 0.30; 0.66; 0.48 scores on a scale — p=0.011
N/A N=49 Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy
Pelvic Organ Prolapse
Primary: Number of Participants With Recurrence of Pelvic Organ Prolapse — 0; 0 Participants
N/A N=100 Clinical Trial Comparing Conventional and Robot-assisted(Da Vinci®)Laparoscopic Interventions for Hysterectomy
Laparoscopic Technique no Switch to Open · Duration of Surgery · Intraoperative Complications
Primary: Duration of Surgery — 75; 106 minutes
N/A N=15 Radiofrequency Ablation of Adenomyosis
Adenomyosis
Primary: Post-operative Evidence of Adenomyoma Tissue Ablation Effect by Area (n) as Assessed by Pathological Analysis — 9; 8; 7; 6 treated areas
Phase 4 N=40 Harmonic ACE®+7 Shears in Laparoscopic Hysterectomy
Benign Disease Where Total Hysterectomy is Indicated
Primary: Percentage of Subjects Achieving Hemostasis at the Named Vessel/Pedicle (UA or UP) on the Left Side. — 97.5 percentage of participants
Early Phase 1 N=103 Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study
Cervical Cancer · Uterine Endometrial Cancer · Ovarian Cancer
Primary: Hospital Stay — 3.0; 3.0 Days — p=0.36
Phase 3 N=68 Multimodal Pain Management After Robotic-Assisted Total Laparoscopic Hysterectomy
Pain, Postoperative
Primary: Total Opioid Pain Medications Required 0-3h Post op in Morphine Milligram Equivalents (MME) — 2.00; 5.32 morphine milligram equivalents (MME)
N/A N=60 Histerectomy Vs Partial Myometrial Resection for Placenta Accreta Spectrum
Placenta Accreta
Primary: Feasibility: Proportion of Eligible Patients Who Agree to Participate in the Study. — 60 Participants
N/A N=84 Urinary Retention After Total Laparoscopic Hysterectomy With Immediate Foley Catheter Removal Versus Backfill Void Trial
Urinary Retention · Voiding Disorders
Primary: Number of Participants With Void Trial Failure Rate — 7; 11 Participants
Phase 2 N=11 Pilot Study of MRI-Guided High Intensity Focused Ultrasound Ablation of Uterine Fibroids
Uterine Fibroids · Uterine Leiomyomata
Primary: Treatment-related Adverse Events (AE) Per Subject Resulting From HIFU Treatment of the Uterine Fibroids — 1.3 treatment-related AE/patient
N/A N=74 HOME Study: Hysteroscopic Office Myomectomy Evaluation
Uterine Fibroids · Polyps
Primary: Percent Reduction in Target Pathology Volume — 96.9; 99.9 percentage of fibriods/polyps
Phase 3 N=41 Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.
Pain, Postoperative
Primary: Pain Reported on the Visual Analogue Scale (VAS) at 30 Minutes Postoperative — 5.7; 3.2 VAS scale 0-10
N/A N=31 ESS505 Pre-hysterectomy Protocol
Contraception
Primary: Number of Occluded Fallopian Tubes 60 Minutes After Placement of the Insert as Measured by an HSG Evaluation — 36; NA; NA; NA Occluded fallopian tubes
N/A N=236 Apical Support During Hysterectomy for Pelvic Organ Prolapse
Pelvic Organ Prolapse
Primary: Proportion of Patients Having Concurrent Apical Suspension Performed — 66 Participants
N/A N=3 Hysteroscopic Cryomyolysis for the Treatment of Submucosal Leiomyomata
Uterine Fibroids · Leiomyoma · Menorrhagia
Primary: Number of Adverse Events — 1 Participants
Phase 4 N=110 Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure
Neuromuscular Blockade · Pain · Laparoscopy
Primary: Shoulder Pain — 14; 30 participants
N/A N=22 Surgicel Snow in Gynecological Surgery
Laparoscopic Hysterectomy
Primary: Change in Bleeding at Specified Time Intervals — 485.7; 199.1 seconds
N/A N=137 Laparoscopic Radiofrequency Ablation (RFA) of Symptomatic Uterine Fibroids
Uterine Fibroids · Uterine Myomas
Primary: Assessment of Menstrual Blood Flow (MBF) at 12 Months Post Procedure — 40.2; 48.8; 59.1; 67.7 Percentage of participants
N/A N=16 Clinical Analysis of Pain After Hysterectomy
Postoperative Pain
Primary: Type of Chronic Pain After Hysterectomy — 5; 4; 6; 1 participants
Phase 4 N=87 TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy
Acute Pain
Primary: Total Opioid Use for Pain Control — 20.8; 25.0 mg Morphine equivalents
N/A N=75 Ultrasound-guided Transversus Abdominis Plane Block After Hysterectomy
Post Operative Pain
Primary: Morphine Consumption — 38.4; 38.6; 42.6 mg
N/A N=35 Ultravision Visual Clearing System in Laparoscopic Hysterectomy and Myomectomy
Pain · Hysterectomy · Myomectomy
Primary: Quality of Surgical Field Visualization — 9; 1; 5; 2 participants
Phase 4 N=60 EXPAREL for Minimally Invasive Supracervical Hysterectomies
Pain
Primary: Pain at 12 Hours — 3.9; 3.7 score on a scale
N/A N=290 MyoSure Hysteroscopic Tissue Removal System Registry Study
Uterine Fibroids · Polyps
Primary: Procedure Efficacy — 95.4 percent of pathology
Phase 4 N=100 RCT Superior Hypogastric Block During LH
Hysterectomy
Primary: Postoperative Pain Scores — 3.9; 4.7 score on a scale
N/A N=73 Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids
Uterine Fibroids (Leiomyomas)
Primary: Evaluation of All Adverse Events Encountered — 0; 0.95 Adverse Device Effects / patient